Zevra Therapeutics Inc (ZVRA)

$11.32 +0.14 (1.25%)
Market Cap 672.23M
Revenue (ttm) 106.47M
Net Income (ttm) 83.23M
EPS (ttm) N/A
PE Ratio 7.08
Forward PE 18.79
Profit Margin 78.17%
Debt to Equity Ratio 0.00
Volume 777,700
Avg Vol 1,624,694
Day's Range N/A - N/A
Shares Out 59.38M
Stochastic %K 55%
Beta 0.91
Analysts Strong Sell
Price Target $25.25

Company Profile

Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 3 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase 3 clinical trial to treat narcolepsy. The company is developing Celiprolol, an investigational p...

Industry: Biotechnology
Sector: Healthcare
Phone: 888 958 1253
Address:
101 Federal Street, Suite 103, Boston, United States
CyberspaceCowboy
CyberspaceCowboy Aug. 15 at 11:05 PM
$ZVRA feels bad man seeing nlst at 1.2 and doing extensive dd and not buying it. Faaaa
0 · Reply
KemPharm_rocks
KemPharm_rocks Aug. 14 at 11:53 PM
$ZVRA That Form 144 notice for Rahsaan Thompson is meaningless. It is standard corporate administrative routine. When executive compensation vest in the form of RSUs, executives typically trigger pre-arranged broker transactions (such as under a Rule 10b5-1 trading plan) to sell a portion of shares to satisfy mandatory tax withholding obligations or diversify personal holdings.
0 · Reply
intowits
intowits Aug. 14 at 9:53 PM
$ZVRA
0 · Reply
KemPharm_rocks
KemPharm_rocks Aug. 14 at 8:17 PM
$ZVRA The 2Q 13F/13G filing deadline is actually 5:30 p.m. this evening, but they can technically keep filing till 10:00 p.m., but those won’t appear on http://fintel.io until Monday, probably EOD. Ah well, the tried and true military slogan prevails again, “Hurry up and wait!” 🤪
1 · Reply
KemPharm_rocks
KemPharm_rocks Aug. 14 at 8:08 PM
$ZVRA Next week should be damn interesting 😜, the shorts’ attempting to squash this to $10.00, and the tutes looking to bottom-feed their play.
0 · Reply
KemPharm_rocks
KemPharm_rocks Aug. 14 at 8:04 PM
$ZVRA Hi! 👋🏻 on 6/30/2026
1 · Reply
ekoostik16
ekoostik16 Aug. 14 at 8:03 PM
$ZVRA Not a bad way to head into the weekend.
1 · Reply
M_OF_E
M_OF_E Aug. 14 at 7:08 PM
$ZVRA Arrowstreet Capital, Limited Partnership 6/30/2026 597,162 597,162 New $6,676
0 · Reply
steven1x
steven1x Aug. 14 at 5:29 PM
$ZVRA c https://investors.zevra.com/node/15161/html
0 · Reply
KemPharm_rocks
KemPharm_rocks Aug. 14 at 4:20 PM
$ZVRA Woodline Partners LP just dropped their 13G, notifying everyone of their 8.1% ownership of Zevra, right behind Fidelity’s 8.3% stake!
0 · Reply
Latest News on ZVRA
Zevra Therapeutics Transcript: Canaccord Genuity's 46th Annual Growth Conference

Aug 11, 2026, 11:00 AM EDT - 4 days ago

Zevra Therapeutics Transcript: Canaccord Genuity's 46th Annual Growth Conference

Zevra Therapeutics price target lowered to $23 from $24 at Guggenheim

2026-08-07T11:46:38.000Z - 8 days ago

Zevra Therapeutics price target lowered to $23 from $24 at Guggenheim

Zevra Therapeutics price target raised to $28 from $25 at Citizens

2026-08-06T09:50:22.000Z - 9 days ago

Zevra Therapeutics price target raised to $28 from $25 at Citizens

Zevra Therapeutics Earnings Call Transcript: Q2 2026

Aug 5, 2026, 4:30 PM EDT - 10 days ago

Zevra Therapeutics Earnings Call Transcript: Q2 2026

Zevra Therapeutics Earnings release: Q2 2026

Aug 5, 2026, 4:30 PM EDT - 10 days ago

Zevra Therapeutics Earnings release: Q2 2026

Zevra Therapeutics Quarterly report: Q2 2026

Aug 5, 2026, 4:30 PM EDT - 10 days ago

Zevra Therapeutics Quarterly report: Q2 2026

Zevra Reports Second Quarter 2026 Financial Results and Corporate Update

Aug 5, 2026, 4:05 PM EDT - 10 days ago

Zevra Reports Second Quarter 2026 Financial Results and Corporate Update

Zevra Therapeutics Slides: Corporate presentation

Aug 5, 2026, 4:00 PM EDT - 10 days ago

Zevra Therapeutics Slides: Corporate presentation

Zevra Therapeutics to Present at the Canaccord Genuity Annual Growth Conference

Aug 4, 2026, 7:30 AM EDT - 11 days ago

Zevra Therapeutics to Present at the Canaccord Genuity Annual Growth Conference

Zevra Therapeutics Announces Publication of Four-Year Real-World Data from U.S. Early Access Program Evaluating MIPLYFFA® (arimoclomol) in Niemann-Pick Disease Type C (NPC)

Aug 3, 2026, 7:30 AM EDT - 12 days ago

Zevra Therapeutics Announces Publication of Four-Year Real-World Data from U.S. Early Access Program Evaluating MIPLYFFA® (arimoclomol) in Niemann-Pick Disease Type C (NPC)

ZVRA Investors Have Opportunity to Join Zevra Therapeutics, Inc. Fraud Investigation with SBS Law

Jul 27, 2026, 8:40 PM EDT - 19 days ago

ZVRA Investors Have Opportunity to Join Zevra Therapeutics, Inc. Fraud Investigation with SBS Law

Spruce Biosciences appoints Quartel as Chief Medical Officer

2026-07-27T12:15:58.000Z - 19 days ago

Spruce Biosciences appoints Quartel as Chief Medical Officer

SPRB

Zevra Therapeutics price target lowered to $24 from $29 at Guggenheim

2026-07-27T11:21:03.000Z - 19 days ago

Zevra Therapeutics price target lowered to $24 from $29 at Guggenheim

Zevra Therapeutics price target lowered to $24 from $27 at BTIG

2026-07-27T11:11:18.000Z - 19 days ago

Zevra Therapeutics price target lowered to $24 from $27 at BTIG

Zevra Therapeutics price target lowered to $20 from $29 at Canaccord

2026-07-27T10:45:40.000Z - 19 days ago

Zevra Therapeutics price target lowered to $20 from $29 at Canaccord

EU opinion ‘headwind, but not insurmountable’ for Zevra, says H.C. Wainwright

2026-07-24T15:20:18.000Z - 22 days ago

EU opinion ‘headwind, but not insurmountable’ for Zevra, says H.C. Wainwright

Zevra Therapeutics down 30% at $8.78 after negative CHMP opinion on arimoclomol

2026-07-24T12:25:51.000Z - 22 days ago

Zevra Therapeutics down 30% at $8.78 after negative CHMP opinion on arimoclomol

Zevra Therapeutics announces negative CHMP opinion on arimoclomol MAA

2026-07-24T11:45:45.000Z - 22 days ago

Zevra Therapeutics announces negative CHMP opinion on arimoclomol MAA

Zevra Therapeutics Provides Update on Regulatory Submission for Arimoclomol for the Treatment of Niemann-Pick Disease Type C (NPC) in the European Union

Jul 24, 2026, 7:30 AM EDT - 22 days ago

Zevra Therapeutics Provides Update on Regulatory Submission for Arimoclomol for the Treatment of Niemann-Pick Disease Type C (NPC) in the European Union

Zevra Therapeutics Announces Details for Q2 2026 Financial Results Call

Jul 22, 2026, 7:30 AM EDT - 24 days ago

Zevra Therapeutics Announces Details for Q2 2026 Financial Results Call

Zevra publishes Miplyffa data in Molecular Genetics, Metabolism Reports

2026-06-23T13:33:10.000Z - 7 weeks ago

Zevra publishes Miplyffa data in Molecular Genetics, Metabolism Reports

Zevra Therapeutics Announces Publication of Positive MIPLYFFA® Data from Pediatric Substudy in Infants with Niemann-Pick Disease Type C (NPC)

Jun 23, 2026, 7:30 AM EDT - 7 weeks ago

Zevra Therapeutics Announces Publication of Positive MIPLYFFA® Data from Pediatric Substudy in Infants with Niemann-Pick Disease Type C (NPC)

Zevra Therapeutics chief medical officer to step down

2026-06-11T13:15:49.000Z - 2 months ago

Zevra Therapeutics chief medical officer to step down

Zevra's Chief Medical Officer to Step Down for Personal Reasons as Part of Planned Transition

Jun 11, 2026, 8:30 AM EDT - 2 months ago

Zevra's Chief Medical Officer to Step Down for Personal Reasons as Part of Planned Transition

Zevra Therapeutics price target raised to $35 from $25 at Maxim

2026-06-10T17:36:05.000Z - 2 months ago

Zevra Therapeutics price target raised to $35 from $25 at Maxim

Zevra Therapeutics price target raised to $29 from $25 at Guggenheim

2026-06-10T11:21:28.000Z - 2 months ago

Zevra Therapeutics price target raised to $29 from $25 at Guggenheim

Zevra Therapeutics price target raised to $27 from $23 at BTIG

2026-06-09T17:02:03.000Z - 2 months ago

Zevra Therapeutics price target raised to $27 from $23 at BTIG

Zevra Therapeutics price target raised to $29 from $24 at Canaccord

2026-06-09T11:10:50.000Z - 2 months ago

Zevra Therapeutics price target raised to $29 from $24 at Canaccord

Zevra Therapeutics price target raised to $25 from $18 at Citizens

2026-06-09T09:05:39.000Z - 2 months ago

Zevra Therapeutics price target raised to $25 from $18 at Citizens

Zevra Therapeutics price target raised to $34 from $24 at Cantor Fitzgerald

2026-06-08T14:10:40.000Z - 2 months ago

Zevra Therapeutics price target raised to $34 from $24 at Cantor Fitzgerald

Zevra Therapeutics Announces Orange Book Listing of U.S. Patent Strengthening Exclusivity for MIPLYFFA

Jun 8, 2026, 7:30 AM EDT - 2 months ago

Zevra Therapeutics Announces Orange Book Listing of U.S. Patent Strengthening Exclusivity for MIPLYFFA

Zevra Therapeutics Slides: Corporate presentation

Jun 2, 2026, 7:00 AM EDT - 2 months ago

Zevra Therapeutics Slides: Corporate presentation

Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

May 29, 2026, 4:30 PM EDT - 2 months ago

Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Zevra Therapeutics Transcript: H.C. Wainwright 4th Annual BioConnect Investor Conference

May 19, 2026, 9:00 AM EDT - 3 months ago

Zevra Therapeutics Transcript: H.C. Wainwright 4th Annual BioConnect Investor Conference

Zevra Therapeutics to Present at the H.C. Wainwright BioConnect Investor Conference

May 12, 2026, 7:30 AM EDT - 3 months ago

Zevra Therapeutics to Present at the H.C. Wainwright BioConnect Investor Conference

Zevra Therapeutics Earnings Call Transcript: Q1 2026

May 6, 2026, 4:30 PM EDT - 3 months ago

Zevra Therapeutics Earnings Call Transcript: Q1 2026

Zevra Therapeutics Earnings release: Q1 2026

May 6, 2026, 4:30 PM EDT - 3 months ago

Zevra Therapeutics Earnings release: Q1 2026

Zevra Therapeutics Quarterly report: Q1 2026

May 6, 2026, 4:30 PM EDT - 3 months ago

Zevra Therapeutics Quarterly report: Q1 2026

Zevra Reports First Quarter 2026 Financial Results and Corporate Update

May 6, 2026, 4:05 PM EDT - 3 months ago

Zevra Reports First Quarter 2026 Financial Results and Corporate Update

Zevra Therapeutics Proxy statement: Proxy filing

Apr 20, 2026, 8:00 AM EDT - 4 months ago

Zevra Therapeutics Proxy statement: Proxy filing

Zevra Therapeutics Proxy statement: Proxy filing

Apr 6, 2026, 8:00 AM EDT - 4 months ago

Zevra Therapeutics Proxy statement: Proxy filing

Zevra Therapeutics Slides: Corporate presentation

Apr 6, 2026, 7:00 AM EDT - 4 months ago

Zevra Therapeutics Slides: Corporate presentation

Zevra Therapeutics Reports Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(c)(4)

Mar 20, 2026, 4:30 PM EDT - 5 months ago

Zevra Therapeutics Reports Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(c)(4)

Zevra Therapeutics Sells SDX Portfolio to Commave Therapeutics for $50 Million

Mar 16, 2026, 7:30 AM EDT - 5 months ago

Zevra Therapeutics Sells SDX Portfolio to Commave Therapeutics for $50 Million

Zevra Therapeutics Transcript: The Citizens Life Sciences Conference 2026

Mar 11, 2026, 9:00 AM EDT - 5 months ago

Zevra Therapeutics Transcript: The Citizens Life Sciences Conference 2026

Zevra Therapeutics Earnings Call Transcript: Q4 2025

Mar 9, 2026, 4:30 PM EDT - 5 months ago

Zevra Therapeutics Earnings Call Transcript: Q4 2025

Zevra Therapeutics Annual report: Q4 2025

Mar 9, 2026, 4:30 PM EDT - 5 months ago

Zevra Therapeutics Annual report: Q4 2025

Zevra Therapeutics Earnings release: Q4 2025

Mar 9, 2026, 4:30 PM EDT - 5 months ago

Zevra Therapeutics Earnings release: Q4 2025

Zevra Therapeutics Slides: Corporate presentation

Mar 9, 2026, 7:00 AM EDT - 5 months ago

Zevra Therapeutics Slides: Corporate presentation

Zevra Therapeutics Announces Details for Q4 and Full Year 2025 Financial Results Call

Mar 2, 2026, 7:30 AM EST - 5 months ago

Zevra Therapeutics Announces Details for Q4 and Full Year 2025 Financial Results Call

Zevra Therapeutics to Present at the Citizens Life Sciences Conference

Feb 25, 2026, 7:30 AM EST - 6 months ago

Zevra Therapeutics to Present at the Citizens Life Sciences Conference

Transpire Bio Strengthens its Leadership Team with Appointment of LaDuane Clifton as Chief Financial Officer

Feb 24, 2026, 3:42 PM EST - 6 months ago

Transpire Bio Strengthens its Leadership Team with Appointment of LaDuane Clifton as Chief Financial Officer

Zevra Therapeutics Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Feb 19, 2026, 10:38 AM EST - 6 months ago

Zevra Therapeutics Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Zevra Therapeutics Presents Positive New Real-World Data on MIPLYFFA® in Patients with Neimann-Pick Disease Type C (NPC) at the 22nd Annual WORLDSymposium™

Feb 4, 2026, 7:30 AM EST - 6 months ago

Zevra Therapeutics Presents Positive New Real-World Data on MIPLYFFA® in Patients with Neimann-Pick Disease Type C (NPC) at the 22nd Annual WORLDSymposium™

Zevra Therapeutics to Ring Nasdaq Stock Market Opening Bell on Monday, February 9, 2026

Feb 2, 2026, 7:30 AM EST - 6 months ago

Zevra Therapeutics to Ring Nasdaq Stock Market Opening Bell on Monday, February 9, 2026

Zevra Therapeutics to Present Multiple Analyses on MIPLYFFA® at the 22nd Annual WORLDSymposium™

Jan 26, 2026, 7:30 AM EST - 7 months ago

Zevra Therapeutics to Present Multiple Analyses on MIPLYFFA® at the 22nd Annual WORLDSymposium™

Zevra Therapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 15, 2026, 12:45 PM EST - 7 months ago

Zevra Therapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference

Zevra Therapeutics Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 15, 2026, 12:45 PM EST - 7 months ago

Zevra Therapeutics Slides: 44th Annual J.P. Morgan Healthcare Conference

Zevra Therapeutics, Inc. Appoints Alicia Secor to Board of Directors; Announces Retirement of Wendy Dixon, PhD

Dec 2, 2025, 7:30 AM EST - 9 months ago

Zevra Therapeutics, Inc. Appoints Alicia Secor to Board of Directors; Announces Retirement of Wendy Dixon, PhD

Zevra Therapeutics, Inc. Announces CFO Transition

Nov 20, 2025, 4:05 PM EST - 9 months ago

Zevra Therapeutics, Inc. Announces CFO Transition

Zevra Therapeutics Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Nov 12, 2025, 11:30 AM EST - 9 months ago

Zevra Therapeutics Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Zevra Therapeutics Earnings Call Transcript: Q3 2025

Nov 5, 2025, 4:30 PM EST - 10 months ago

Zevra Therapeutics Earnings Call Transcript: Q3 2025

Zevra Therapeutics Quarterly report: Q3 2025

Nov 5, 2025, 4:30 PM EST - 10 months ago

Zevra Therapeutics Quarterly report: Q3 2025

Zevra Therapeutics Earnings release: Q3 2025

Nov 5, 2025, 4:30 PM EST - 10 months ago

Zevra Therapeutics Earnings release: Q3 2025

Zevra Reports Third Quarter 2025 Financial Results and Corporate Update

Nov 5, 2025, 4:05 PM EST - 10 months ago

Zevra Reports Third Quarter 2025 Financial Results and Corporate Update

Zevra Therapeutics Slides: Corporate Presentation

Nov 4, 2025, 6:00 PM EST - 10 months ago

Zevra Therapeutics Slides: Corporate Presentation

Zevra Therapeutics to Participate in the Guggenheim Healthcare Innovation Conference

Oct 29, 2025, 7:30 AM EDT - 10 months ago

Zevra Therapeutics to Participate in the Guggenheim Healthcare Innovation Conference

Zevra Therapeutics Announces Details for Q3 2025 Financial Results Call

Oct 27, 2025, 7:30 AM EDT - 10 months ago

Zevra Therapeutics Announces Details for Q3 2025 Financial Results Call

Zevra Therapeutics Announces Upcoming Oral Presentation at the International Niemann-Pick Disease Alliance (INPDA) Meeting and Poster Presentations at the Child Neurology Society (CNS) Conference on MIPLYFFA® (arimoclomol) and OLPRUVA® (sodium phenylbutyrate)

Sep 18, 2025, 7:30 AM EDT - 11 months ago

Zevra Therapeutics Announces Upcoming Oral Presentation at the International Niemann-Pick Disease Alliance (INPDA) Meeting and Poster Presentations at the Child Neurology Society (CNS) Conference on MIPLYFFA® (arimoclomol) and OLPRUVA® (sodium phenylbutyrate)

Zevra Therapeutics Presents Positive New Data Supporting Foundational Role of MIPLYFFA® (arimoclomol) for the Treatment of Niemann-Pick Disease Type C at the International Congress of Inborn Errors of Metabolism (ICIEM)

Sep 4, 2025, 7:30 AM EDT - 1 year ago

Zevra Therapeutics Presents Positive New Data Supporting Foundational Role of MIPLYFFA® (arimoclomol) for the Treatment of Niemann-Pick Disease Type C at the International Congress of Inborn Errors of Metabolism (ICIEM)

Zevra Therapeutics Transcript: Cantor Global Healthcare Conference 2025

Sep 3, 2025, 11:30 AM EDT - 1 year ago

Zevra Therapeutics Transcript: Cantor Global Healthcare Conference 2025

Zevra Therapeutics Announces Multiple Datasets on MIPLYFFA® (arimoclomol) to be Presented at the International Congress of Inborn Errors of Metabolism (ICIEM)

Aug 28, 2025, 7:30 AM EDT - 1 year ago

Zevra Therapeutics Announces Multiple Datasets on MIPLYFFA® (arimoclomol) to be Presented at the International Congress of Inborn Errors of Metabolism (ICIEM)

Zevra Therapeutics to Participate at Upcoming Investor Conferences in September

Aug 26, 2025, 7:30 AM EDT - 1 year ago

Zevra Therapeutics to Participate at Upcoming Investor Conferences in September

Zevra Therapeutics Transcript: Canaccord Genuity’s 45th Annual Growth Conference

Aug 13, 2025, 1:00 PM EDT - 1 year ago

Zevra Therapeutics Transcript: Canaccord Genuity’s 45th Annual Growth Conference

Zevra Therapeutics Earnings Call Transcript: Q2 2025

Aug 12, 2025, 4:30 PM EDT - 1 year ago

Zevra Therapeutics Earnings Call Transcript: Q2 2025

Zevra Therapeutics Quarterly report: Q2 2025

Aug 12, 2025, 4:30 PM EDT - 1 year ago

Zevra Therapeutics Quarterly report: Q2 2025

Zevra Therapeutics Earnings release: Q2 2025

Aug 12, 2025, 4:30 PM EDT - 1 year ago

Zevra Therapeutics Earnings release: Q2 2025

Zevra Reports Second Quarter 2025 Financial Results and Corporate Update

Aug 12, 2025, 4:05 PM EDT - 1 year ago

Zevra Reports Second Quarter 2025 Financial Results and Corporate Update

Zevra Therapeutics Slides: Corporate Presentation

Aug 12, 2025, 4:00 PM EDT - 1 year ago

Zevra Therapeutics Slides: Corporate Presentation

Zevra Therapeutics Announces Details for Q2 2025 Financial Results Call

Aug 4, 2025, 7:30 AM EDT - 1 year ago

Zevra Therapeutics Announces Details for Q2 2025 Financial Results Call

Zevra Therapeutics Submits Marketing Authorization Application to European Medicines Agency to Review Arimoclomol for the Treatment of Niemann-Pick Disease Type C

Jul 28, 2025, 6:00 AM EDT - 1 year ago

Zevra Therapeutics Submits Marketing Authorization Application to European Medicines Agency to Review Arimoclomol for the Treatment of Niemann-Pick Disease Type C

Zevra Therapeutics Announces MIPLYFFA® and OLPRUVA® Presentations at the Annual Meeting of the Southeastern Regional Genetics Group (SERGG)

Jul 18, 2025, 7:30 AM EDT - 1 year ago

Zevra Therapeutics Announces MIPLYFFA® and OLPRUVA® Presentations at the Annual Meeting of the Southeastern Regional Genetics Group (SERGG)

Zevra Therapeutics Announces Open Label Extension Data Showing Sustained Long-Term Efficacy of MIPLYFFA for the Treatment of NPC Published in the Journal of Molecular Genetics and Metabolism

Jul 16, 2025, 7:30 AM EDT - 1 year ago

Zevra Therapeutics Announces Open Label Extension Data Showing Sustained Long-Term Efficacy of MIPLYFFA for the Treatment of NPC Published in the Journal of Molecular Genetics and Metabolism

Zevra Therapeutics Slides: Corporate Presentation

Jun 2, 2025, 7:00 AM EDT - 1 year ago

Zevra Therapeutics Slides: Corporate Presentation

Zevra Announces Final Results of 2025 Annual Meeting of Stockholders

May 29, 2025, 4:35 PM EDT - 1 year ago

Zevra Announces Final Results of 2025 Annual Meeting of Stockholders

Zevra Therapeutics Proxy statement: Proxy Filing

May 21, 2025, 8:00 AM EDT - 1 year ago

Zevra Therapeutics Proxy statement: Proxy Filing

All Three Leading Proxy Advisory Firms – ISS, Glass Lewis, and Egan-Jones – Recommend Zevra Stockholders Vote FOR the Company's Director Nominees

May 21, 2025, 7:30 AM EDT - 1 year ago

All Three Leading Proxy Advisory Firms – ISS, Glass Lewis, and Egan-Jones – Recommend Zevra Stockholders Vote FOR the Company's Director Nominees

Zevra Therapeutics Transcript: H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025

May 20, 2025, 12:30 PM EDT - 1 year ago

Zevra Therapeutics Transcript: H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025

Zevra Therapeutics Earnings Call Transcript: Q1 2025

May 13, 2025, 4:30 PM EDT - 1 year ago

Zevra Therapeutics Earnings Call Transcript: Q1 2025

Zevra Therapeutics Quarterly report: Q1 2025

May 13, 2025, 4:30 PM EDT - 1 year ago

Zevra Therapeutics Quarterly report: Q1 2025

Zevra Therapeutics Earnings release: Q1 2025

May 13, 2025, 4:30 PM EDT - 1 year ago

Zevra Therapeutics Earnings release: Q1 2025

Zevra Therapeutics Proxy statement: Proxy Filing

May 8, 2025, 8:00 AM EDT - 1 year ago

Zevra Therapeutics Proxy statement: Proxy Filing

Zevra Therapeutics Transcript: The Citizens JMP Life Sciences Conference 2025

May 7, 2025, 11:30 AM EDT - 1 year ago

Zevra Therapeutics Transcript: The Citizens JMP Life Sciences Conference 2025

Zevra Therapeutics Announces Details for Q1 2025 Financial Results Call

May 6, 2025, 7:30 AM EDT - 1 year ago

Zevra Therapeutics Announces Details for Q1 2025 Financial Results Call

Zevra Therapeutics Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Zevra Therapeutics Proxy statement: Proxy Filing

Zevra Therapeutics Proxy statement: Proxy Filing

Apr 21, 2025, 8:00 AM EDT - 1 year ago

Zevra Therapeutics Proxy statement: Proxy Filing

Zevra Therapeutics Proxy statement: Proxy Filing

Apr 21, 2025, 8:00 AM EDT - 1 year ago

Zevra Therapeutics Proxy statement: Proxy Filing

Zevra Therapeutics Proxy statement: Proxy Filing

Apr 21, 2025, 8:00 AM EDT - 1 year ago

Zevra Therapeutics Proxy statement: Proxy Filing

Zevra Announces Publication of MIPLYFFA® Mechanism of Action Manuscript in Molecular Genetics and Metabolism

Apr 17, 2025, 7:30 AM EDT - 1 year ago

Zevra Announces Publication of MIPLYFFA® Mechanism of Action Manuscript in Molecular Genetics and Metabolism

Zevra Therapeutics Proxy statement: Proxy Filing

Apr 10, 2025, 8:00 AM EDT - 1 year ago

Zevra Therapeutics Proxy statement: Proxy Filing

Zevra Therapeutics Proxy statement: Proxy Filing

Apr 7, 2025, 8:00 AM EDT - 1 year ago

Zevra Therapeutics Proxy statement: Proxy Filing

Zevra Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $150 Million

Apr 7, 2025, 7:30 AM EDT - 1 year ago

Zevra Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $150 Million

Zevra Therapeutics Files Preliminary Proxy

Mar 31, 2025, 4:12 PM EDT - 1 year ago

Zevra Therapeutics Files Preliminary Proxy

Zevra Therapeutics Proxy statement: Proxy Filing

Mar 31, 2025, 8:00 AM EDT - 1 year ago

Zevra Therapeutics Proxy statement: Proxy Filing

Zevra Therapeutics Proxy statement: Proxy Filing

Mar 31, 2025, 8:00 AM EDT - 1 year ago

Zevra Therapeutics Proxy statement: Proxy Filing

Zevra Therapeutics Proxy statement: Proxy Filing

Mar 31, 2025, 8:00 AM EDT - 1 year ago

Zevra Therapeutics Proxy statement: Proxy Filing

Zevra Therapeutics Earnings Call Transcript: Q4 2024

Mar 11, 2025, 4:30 PM EDT - 1 year ago

Zevra Therapeutics Earnings Call Transcript: Q4 2024

Zevra Therapeutics Annual report: Q4 2024

Mar 11, 2025, 4:30 PM EDT - 1 year ago

Zevra Therapeutics Annual report: Q4 2024

Zevra Therapeutics Earnings release: Q4 2024

Mar 11, 2025, 4:30 PM EDT - 1 year ago

Zevra Therapeutics Earnings release: Q4 2024

Zevra Reports Full Year 2024 and Fourth Quarter Financial Results

Mar 11, 2025, 4:05 PM EDT - 1 year ago

Zevra Reports Full Year 2024 and Fourth Quarter Financial Results

Zevra Therapeutics Transcript: TD Cowen 45th Annual Healthcare Conference

Mar 5, 2025, 10:30 AM EST - 1 year ago

Zevra Therapeutics Transcript: TD Cowen 45th Annual Healthcare Conference

Zevra Launches New Disease State Awareness Campaign, ‘Learn NPC, Read Between the Signs,' to Drive Early Recognition and Treatment of Niemann-Pick Disease Type C

Feb 28, 2025, 7:30 AM EST - 1 year ago

Zevra Launches New Disease State Awareness Campaign, ‘Learn NPC, Read Between the Signs,' to Drive Early Recognition and Treatment of Niemann-Pick Disease Type C

Zevra Therapeutics Enters Agreement to Sell its Rare Pediatric Disease Priority Review Voucher for $150 Million

Feb 27, 2025, 7:30 AM EST - 1 year ago

Zevra Therapeutics Enters Agreement to Sell its Rare Pediatric Disease Priority Review Voucher for $150 Million

Zevra to Report 2024 Fourth Quarter and Full Year Financial Results

Feb 26, 2025, 9:46 AM EST - 1 year ago

Zevra to Report 2024 Fourth Quarter and Full Year Financial Results

CyberspaceCowboy
CyberspaceCowboy Aug. 15 at 11:05 PM
$ZVRA feels bad man seeing nlst at 1.2 and doing extensive dd and not buying it. Faaaa
0 · Reply
KemPharm_rocks
KemPharm_rocks Aug. 14 at 11:53 PM
$ZVRA That Form 144 notice for Rahsaan Thompson is meaningless. It is standard corporate administrative routine. When executive compensation vest in the form of RSUs, executives typically trigger pre-arranged broker transactions (such as under a Rule 10b5-1 trading plan) to sell a portion of shares to satisfy mandatory tax withholding obligations or diversify personal holdings.
0 · Reply
intowits
intowits Aug. 14 at 9:53 PM
$ZVRA
0 · Reply
KemPharm_rocks
KemPharm_rocks Aug. 14 at 8:17 PM
$ZVRA The 2Q 13F/13G filing deadline is actually 5:30 p.m. this evening, but they can technically keep filing till 10:00 p.m., but those won’t appear on http://fintel.io until Monday, probably EOD. Ah well, the tried and true military slogan prevails again, “Hurry up and wait!” 🤪
1 · Reply
KemPharm_rocks
KemPharm_rocks Aug. 14 at 8:08 PM
$ZVRA Next week should be damn interesting 😜, the shorts’ attempting to squash this to $10.00, and the tutes looking to bottom-feed their play.
0 · Reply
KemPharm_rocks
KemPharm_rocks Aug. 14 at 8:04 PM
$ZVRA Hi! 👋🏻 on 6/30/2026
1 · Reply
ekoostik16
ekoostik16 Aug. 14 at 8:03 PM
$ZVRA Not a bad way to head into the weekend.
1 · Reply
M_OF_E
M_OF_E Aug. 14 at 7:08 PM
$ZVRA Arrowstreet Capital, Limited Partnership 6/30/2026 597,162 597,162 New $6,676
0 · Reply
steven1x
steven1x Aug. 14 at 5:29 PM
$ZVRA c https://investors.zevra.com/node/15161/html
0 · Reply
KemPharm_rocks
KemPharm_rocks Aug. 14 at 4:20 PM
$ZVRA Woodline Partners LP just dropped their 13G, notifying everyone of their 8.1% ownership of Zevra, right behind Fidelity’s 8.3% stake!
0 · Reply
ZVRA100
ZVRA100 Aug. 14 at 3:58 PM
$ZVRA woodline partners now own 4.8M shares of zvra.
1 · Reply
MikeyNJ
MikeyNJ Aug. 14 at 2:21 PM
$ZVRA The action continues in the December 2027 option chain centered around the $12 puts. Every day this week they trade on an algo and by midday the volume usually peaks. The open interest just in the put chain is over 6000 contracts and increasing daily by 1000+.
1 · Reply
ZVRA100
ZVRA100 Aug. 14 at 2:12 PM
$ZVRA why cant we go like $ETON ….
1 · Reply
BMW2002
BMW2002 Aug. 14 at 11:45 AM
$ZVRA .
0 · Reply
DevAd
DevAd Aug. 14 at 8:34 AM
$ZVRA can we sell the company, already. 20-25. Less gooo!
2 · Reply
KemPharm_rocks
KemPharm_rocks Aug. 13 at 11:19 PM
$ZVRA One more day to go, for a clean snapshot of what institutional ownership percentage was, back on 6/30/2026. But today's numbers reflected a whopping 89.25%. Go ask your AI what that means, going forward, for the MMs who will be aggressively trying to pin Zevra at $10.00 on August 21, for max-pain to option-holders. They might be facing a tug-o-war with bargain-hunters. This is not a $10 stock. Repeat, this is not a $10 stock. 😉
0 · Reply
intowits
intowits Aug. 13 at 10:01 PM
$ZVRA AI Conversation: what are the odds of a successful re-examination of a chmp negative maa opinion? The odds of successfully reversing a Committee for CHMP negative MAA opinion during a re-examination are low, ranging between 20% & 25%. While rare high-profile reversals do happen—such as the CHMP's positive turnaround for Leqembi after an initial rejection—overturning a decision requires strict adherence to narrow procedural limits. No new info, most negative opinions stem from fundamental study-design limitations or insufficient evidence of efficacy. These core clinical deficiencies are almost impossible to fix post-trial. 90% of fda approved drugs are also approved by the EMA. Great to know that we are that 1 in 10 dog.
2 · Reply
intowits
intowits Aug. 13 at 6:40 PM
$ZVRA hugging the bottom of the range
0 · Reply
KemPharm_rocks
KemPharm_rocks Aug. 13 at 4:13 PM
$ZVRA This message board is an absolute ghost-town. 🙏 that the retail who were looking to flip a quick buck, have decided to pack up their marbles and find another ticker symbol to haunt, going forward. That said, for the serious, long-term investors with the intelligence of DD, Zevra remains a durable, small-cap biotech company with commercial momentum, a strong balance sheet, no debt, and two, defined, regulatory events in 2026, that will clarify the Miplyffa European optionality and the Celiprolol U.S. pathway timing. The core U.S. business continues to compound the existing 6/30/2026 reported $260 cash/cash equivalents. On this, we stand our ground.
0 · Reply
Biotechnicity
Biotechnicity Aug. 13 at 3:21 PM
$ZVRA Does anyone remember Soleno Therapeutics going from a market-cap of $7M(?) to over $2BN on the strength of its Prader-Willi drug approval. I kicked myself for not buying shares when I saw it as a likely acquisition target of Kempharm/Zevra back in the day. The stock price was something like $0.17 a share. It was bought out somewhat recently by Neurocrine for $53 a share. They (Neurocrine) have a portfolio of 3-rare disease drugs. When we think buyout rarely does a player like Neurocrine come to mind. But at a market-cap of $15BN they certainly could work a deal if Neil was receptive. In their position, acquiring the cash and a profitable drug might be a perfect match. Lots of possibilities. Let’s see where this goes! https://investors.soleno.life/news-releases/news-release-details/neurocrine-acquire-soleno-therapeutics-expanding-its
1 · Reply
KemPharm_rocks
KemPharm_rocks Aug. 13 at 1:44 AM
$ZVRA I reiterate this point below. Between now and Q3 (~November 5), we might get lucky with timing on news of the FDA Type-C follow-up meeting. But if not, we still have at least two conferences in early September to eyeball: Cantor Global Healthcare Conference & H.C. Wainwright Global Investment Conference (and the Guggenheim Healthcare Innovation Conference in mid-November). Institutional ownership looks pretty maxed out already, but every last drip in the institutional bucket of the Zevra Express, only helps. For now, all eyes on this Friday’s post-45-day Q2 deadline (6/30/2026) 13F/13G reporting. You don’t even need to be able to pass the marshmallow test to wait that long.
1 · Reply
lebrian_james
lebrian_james Aug. 12 at 8:50 PM
$ZVRA Corey Watton -- really inspiring confidence as a board member... what a stooge.
3 · Reply